Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Launched by CHENG-HSIN GENERAL HOSPITAL · Aug 17, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well certain blood markers can predict outcomes for patients with acute heart failure (AHF), especially those who also have chronic kidney disease (CKD). AHF is a serious condition where the heart struggles to pump blood effectively, often leading to hospital stays, particularly in older adults. Researchers want to see if a new approach, called plasma proteomics, can provide better insights compared to the currently used marker, NT-pro-BNP, which doesn’t always work well for patients with CKD.

To participate in the trial, you need to be hospitalized for acute heart failure. However, some people may not be eligible, such as those with very low NT-pro-BNP levels, pregnant individuals, those with amputations, or patients on regular dialysis for end-stage kidney disease. If you join the study, you’ll help researchers understand how to better predict health outcomes for patients like you or your loved ones facing these challenging conditions. The trial is currently recruiting participants of all ages and genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • hospitalized for acute heart failure
• Exclusion Criteria:
• • initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis